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Abstract
Malignant neoplasms are the leading cause of death in Korea. We aimed to examine if metformin use in cancer survivors reduces all-
cause mortality. This study was retrospectively designed based on data from the Korean National Health Insurance Service-National
Health Screening Cohort (HEALS) between 2002 and 2015. The Kaplan–Meier estimator and log-rank test was performed to
estimate the survival function according to metformin usage (3721 metformin non-users with diabetes, 5580 metformin users with
diabetes, and 24,483 non-diabetic individuals). Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause
mortality were calculated using Cox proportional hazards regression models.
The median follow-up duration was 4.2years. The HRs (95% CIs) for all-cause mortality of metformin users and the non-diabetic
group were 0.762 (0.683–0.850) and 1.055 (0.966–1.152) in men and 0.805 (0.649–0.999), and 1.049 (0.873–1.260) in women,
respectively, compared with metformin non-users among diabetic cancer survivors, in a fully adjusted model. After stratifying
metformin users into pre- and post-diagnosis of cancers, adjusted HRs (95%CIs) of pre- and post-diagnosis metformin users for all-
cause mortality were 0.948 (0.839–1.071) and 0.530 (0.452–0.621) in men and 1.163 (0.921–1.469) and 0.439 (0.323–0.596) in
women, respectively.
Metformin use in cancer survivors with diabetes reduced overall mortality rates. In particular, metformin use after cancer diagnosis,
not before cancer diagnosis, was inversely associated with overall mortality.
Active treatment with metformin for diabetic cancer survivors after cancer diagnosis can improve their survival rates.
Abbreviations: ALT = alanine aminotransferase, AMP = adenosine monophosphate, AMPK = adenosine monophosphate
kinase, ATP= adenosine triphosphate, BMI= bodymass index, CI= confidence interval, Cox-PH=Cox-proportional hazard, CVD=
cardiovascular disease, DM = diabetes mellitus, HEALS = national health screening cohort, HR = hazard ratio, ICD = international
classification of disease, NHIS = national health insurance service, SBP = systolic blood pressure.
Keywords: cancer survivorship, malignant neoplasm, metformin, mortality, non-insulin treated type 2 diabetesEditor: Jianxun Ding.
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Malignant neoplasms are the number 1 cause of death in
Korea.[1] The age-standardized rate of cancer incidence in Korea
was 282.8 per 100,000 persons in 2017.[2] The cancer incidence
and mortality rates have been decreasing (annual percent change,
3.1% for incidence and 2.7% for mortality), while the 5-year
relative survival rate for cancer patients has increased.[3] As
cancer survival rates have gradually improved, the number of
cancer survivors also increased by approximately 1.87 million in
2018.[2] The main concerns for cancer survivors are fear of
recurrence or metastasis of the primary cancer and premature
death. To reduce recurrence, metastasis, and premature death,
strict management of chronic diseases such as diabetes mellitus
(DM) and vigilant surveillance and prevention of cancer have
become very important, especially in long-term cancer survivors.
DM is prevailing in the world and has become a threat to
public health. DM is the 6th most common cause of death in
Korea in 2018 and its prevalence was 14.4% in adults aged 30
years and older in 2016.[1,4] The prevalence of DM in cancer
survivors is higher and its control rate in cancer survivors is lower
than in individuals who have not been diagnosed with cancer.[5]
DM is closely related to cancer development and poor clinical
outcomes, in addition to atherosclerotic cardiovascular diseases
(CVDs).[6] Intensive treatment of early phase diabetes with
lifestyle modification and metformin medication can reduce
diabetes-related events such as atherosclerotic CVDs and
death.[7]
Metformin is a biguanide drug that is used as the first treatment
option in managing diabetes.[8] Although the exact mechanism
underlying how metformin controls blood glucose levels has not
been elucidated, inhibition of hepatic gluconeogenesis, and
enhancement of peripheral insulin sensitivity such as in muscle
seem to be the main mechanisms for glycemic control.[9]
Metformin has pleiotropic effects beyond glucose-lowering
activity. Metformin has been shown to prevent carcinogenesis
and modulate the immune response, and these activities may be
mediated by adenosine monophosphate (AMP)-activated protein
kinase (AMPK).[9,10] These beneficial health effects of metformin
could improve the health and longevity of cancer survivors with
DM.
Evidence on whether metformin use in overall cancer survivors
with DM reduces all-cause death is lacking. We aimed to
investigate the association between metformin use and overall
death among Korean cancer survivors using the Korean National
Health Insurance Service (NHIS)-National Health Screening
Cohort (HEALS) database.
2. Methods selection of research subjects
The NHIS-HEALS cohort data between 2002 and 2015 provided
by the Korean NHIS were used. The cohort consists of 514,794
subjects, which represents a random sample out of the 5.15
million people who undertook medical check-ups between 2002
and 2003. The cohort included individuals aged 40 to 79years as
of December 2002. Age, sex, socioeconomic levels, and medical
information such as medical care information, death-related
information, prescription, and past medical history were
included. Biennial health check-up records between 2002 and
2015 for most subjects were available in this cohort.
Figure 1 Shows a flowchart for patient selection. Subjects who
were diagnosed with cancer once or more during hospitalization
according to the International Classification of Diseases, Tenth2
Revision (ICD-10) code (C00-C97) between 2002 and 2015 were
selected (n=52,499). Subjects who met any of the following
conditions were excluded:1. subjects who were 70years or older between 2004 and 2005
(n=9777),2. subjects who died within 1 year after being enrolled in the
study in the study (n=6434),3. subjects who had taken metformin for 30days or less (n=
486),4. subjects with missing values in confounding variables (n=
1440),5. non-diabetic subjects whowere prescribed metformin between
2002 and 2015 (n=123), or6. subjects with a total study duration of 30days or less (n=455).
Finally, 33,784 subjects (24,483 non-diabetic individuals,
3721 metformin non-users, and 5580 metformin users) were
included in this analysis.
This study followed the 1964 Declaration of Helsinki, and the
Institutional Review Board of Chungbuk National University
approved this study (CBNUH 2020-03-024).2.1. Definition of subject groups
In this study, diabetic patients were defined as 1) subjects who
were diagnosed with diabetes (ICD-10 code: E11-14) and were
prescribed anti-diabetic medication such as insulin, sulfonylurea,
metformin, thiazolidinedione, dipeptidyl peptidase-4 inhibitor,
a-glucosidase inhibitor, sodium-glucose cotransporter-2 inhibi-
tor, glucagon-like peptide-1 agonist and other glucose-lowering
agents for 90days or longer or 2) subjects with fasting blood
glucose ≥ 126mg/dl. Based on the above definition of diabetes,
the study subjects were divided as follows: the non-diabetic
group, subjects without DM; metformin non-users, subjects with
DM who were prescribed other anti-diabetic drugs except for
metformin or metformin for less than 90days between 2002 and
2015; and metformin users, subjects with DM who were
prescribed metformin for at least 90days. Metformin users were
further stratified into pre- and post-diagnosis user groups. The
pre-/post-diagnosis metformin users were determined based on
whether the initial prescription date for metformin was before or
after the initial cancer diagnosis.
The start date of the study was the date of the initial cancer
diagnosis as a main sick code when hospitalized between 2002
and 2015. Since the primary event of interest was death, the study
end date was the date of death by subject. For the subjects who
survived, the last date of medical records became the end of study
among health check-ups, hospital visit, or metformin intake date
if available.2.2. Definition of variables
In this study, potential confounders that might have spurious
association between metformin use and all-cause mortality
among cancer survivors were considered. The variables were
age, body mass index (BMI), systolic blood pressure (SBP),
fasting blood glucose, total cholesterol, alanine aminotransferase
(ALT), hypertension history, physical activity, tobacco-smoking
status, alcohol-drinking status, and economic status. BMI (unit
kg/m2) was defined as bodyweight (kg) divided by squared height
(m). Hypertension history, tobacco-smoking, alcohol consump-
tion, physical activity, and economic status were categorical
Figure 1. Flowchart of inclusion and exclusion criteria.
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questionnaires. Tobacco-smoking status was divided into never
smokers (who had never smoked tobacco) and ever smokers
(who currently smoked or ever smoked tobacco). Alcohol-
drinking status was categorized into rare (less than twice per
month), sometimes (twice per month to twice per week), and
regular (more than 3 times per week). Physical activity was
classified into rare (rarely engage in exercise), sometimes (engage
in exercise 1–4 days per week), and regular (engage in exercise 5
or more days per week). Economic status was stratified into low
(the 0–3rd decile), middle (the 4th–7th decile), and high (the 8th–
10th decile) according to monthly household income.2.3. Statistical analysis
To compare the groups in baseline characteristics, analysis of
variance (ANOVA) and Chi-Squared analysis were performed.
Kaplan–Meier method and log-rank test are employed for
nonparametric estimation and test of survival rates. To calculate
hazard ratios (HRs) and 95% confidence intervals (CIs), Cox-
proportional hazard (Cox-PH) regression models were con-
ducted after metformin non-users were set as the reference. In this
study, 3 Cox-PH regression models were considered, depending
on the levels of confounders:1. Model 1, age only;
2. Model 2, BMI, SBP, ALT, total cholesterol, and fasting blood
glucose, in addition to the variable (age) in Model 1; and
3. Model 3, smoking status, drinking status, physical activity,
economic status, and hypertension history, in addition to
variables in Model 2.3
For analysis, SAS enterprise guide version 7.1 (SAS Institute
Inc., Cary, NC) and R study (version 3.3.3) were used. P values
were tested on both sides, and the significance level was P< .05.3. Results
The median follow-up duration was 4.2years (3.8years in men
and 4.8years in women). Table 1 presented the baseline
characteristics of participants according to metformin use and
diabetes diagnosis by sex. Metformin users with DM were the
oldest patient group and had the highest levels of BMI, SBP,
fasting glucose, and ALT in both sexes (all P values <.001). In
addition, higher percentages of patients with hypertension and
regular physical activity were observed in metformin users
comparedwith the other 2 groups in both sexes. The non-diabetic
group was in higher economic status than metformin non-users
and users in both sexes.
The association betweenmetformin use and all-cause mortality
incidence of cancer survivors was presented in Figure 2. An
estimated cumulative incidence of mortality was calculated using
Kaplan–Meier survival curve. The survival rate of cancer
survivors was significantly higher in the non-diabetic group
than in individuals with DM including metformin non-users and
users in men (log-rank test P value <.001 in men), while the
difference was not statistically significant in women.
Table 2 demonstrated the HRs (95% CIs) from Cox-PH
regression models for all-cause mortality according to metformin
use and the presence of diabetes. The HRs (95% CIs) of
metformin users and the non-diabetic group for all-cause
mortality were 0.775 (0.697–0.863) and 0.925 (0.850–1.007)
Table 1
Baseline characteristics according to metformin use and the presence of diabetes diagnosis by sex.
Men Metformin non-users Metformin users Non-diabetic group P values
Number 2726 3620 13,015
Age, years 58.3±7.3 59.1±7.1 57.8±7.6 <.001
Body mass index, kg/m2 23.9±3.0 24.8±3.0 23.7±2.8 <.001
Systolic blood pressure, mm Hg 130.0±16.9 130.9±17.0 127.1±16.1 <.001
Fasting Glucose, mg/dl 113.6±36.7 134.5±51.9 92.8±11.9 <.001
Total cholesterol, mg/dl 190.0±39.7 192.0±40.9 191.1±36.1 .119
ALT, m/L 33.0±34.6 34.6±28.7 28.7±26.6 <.001
Hypertension, % 16.7 24.2 12.5 <.001
Ever smokers, % 52.9 51.9 49.6 .002
Drinking status, % <.001
Rare 42.1 44.8 43.7
Sometimes 36.0 35.6 38.1
Often 22.0 19.7 18.1
Physical activity, % <.001
Rare 45.4 44.1 45.3
Sometimes 41.7 42.0 43.1
Regular 12.9 14.0 11.5
Economic status, % <.001
Low 22.9 20.2 17.9
Middle 34.2 32.5 32.4
High 42.9 47.3 49.8
Women Metformin non-users Metformin users Non-diabetic group P values
Number 995 1,960 11,468
Age, years 57.8±7.8 58.9±7.5 55.1±7.6 <.001
Body mass index, kg/m2 24.4±3.2 25.7±3.5 23.8±3.0 <.001
Systolic blood pressure, mm Hg 127.9±16.7 130.2±18.0 123.0±16.6 <.001
Fasting Glucose, mg/dl 107.7±40.8 126.3±48.1 90.5±10.7 <.001
Total cholesterol, mg/dl 200.8±39.9 205.6±46.8 199.1±36.8 <.001
ALT, m/L 24.6±17.5 28.3±19.4 22.1±18.6 <.001
Hypertension, % 21.6 33.9 13.4 <.001
Ever smokers, % 2.5 3.2 2.8 .446
Drinking status, % <.001
Rare 85.9 88.6 84.3
Sometimes 12.5 10.2 14.2
Often 1.6 1.2 1.5
Physical activity, % <.001
Rare 56.5 55.8 54.7
Sometimes 31.8 29.9 34.5
Regular 11.8 14.3 10.8
Economic status, % <.001
Low 26.0 25.4 22.8
Middle 36.8 34.4 33.0
High 37.2 40.2 44.2
Values are presented as n (%) or mean ± standard errors.
P values are determined for continuous variables by ANOVA test and for categorical variables by Chi-Squared test.
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women, respectively, compared with metformin non-users, after
adjusting for age only (Model 1). The HRs (95% CIs) of
metformin users and the non-diabetic group were 0.762 (0.683–
0.850) and 1.055 (0.966–1.152) inmen and 0.805 (0.649–0.999)
and 1.049 (0.873–1.260) in women, respectively, compared with
metformin non-users, after adjusting for age, BMI, SBP, ALT,
total cholesterol, fasting blood glucose, smoking status, drinking
status, physical activity, economic status, and hypertension
history (Model 3).
To determine whether metformin use before and after cancer
diagnosis reduced all-cause mortality in cancer survivors,
metformin users were stratified into pre- and post-diagnosis
metformin users (Table 3). The HRs (95% CIs) of pre- and post-4
diagnosis metformin users were 0.948 (0.839–1.071) and 0.530
(0.452–0.621) in men and 1.163 (0.921–1.469) and 0.439
(0.323–0.596) in women, respectively, comparedwith metformin
non-users, after fully adjusting for potential confounding factors
(Model 3).4. Discussion
These findings from the current study indicated that among
cancer survivors, metformin users with diabetes had a higher
survival rate than metformin non-users. In particular, individuals
who had taken metformin since they were diagnosed with cancer
were at a lower risk of death, after fully adjusting for potential
confounding factors.
Figure 2. The estimated cumulative incidence of all-cause mortality using Kaplan–Meier estimates among cancer survivors according to metformin use and the
presence of diabetes. P values are from log-rank tests.
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metformin use and overall survival among survivors who
experienced individual cancer such as colorectal, breast, and
pancreatic cancer[11–13]; however, there are still conflicting
findings to show null association. [14,15] In addition, only a
few studies reported the association between metformin and
overall cancer types, rather than individual type of cancer.[16] The
significant relationship between metformin use and lower
mortality was observed among cancer survivors who were
diagnosed with individual type of cancer (colorectum, breast,
pancreas, and so on).[11–13] However, Lega et al observed that
metformin use did not show a benefit for overall and breast
cancer-specific survival.[14] Cossor et al demonstrated that
colorectal cancer survivors with metformin medication did not
show better survival.[15] Yin et al conducted a systematic review
and meta-analysis, showing an overall survival benefit of
metformin for cancer survivors.[17] In the meta-analysis, a
reduction in all-cause mortality was seen in survivors of lung,
breast, prostate, pancreatic, and colorectal cancer.[17] Currie et al
reported that compared with other anti-diabetic drugs, metfor-
min had a beneficial impact on survival among mixed type cancer
survivors.[16] Besides Currie research, there is lack of evidence
examining the beneficial effects of metformin use on all-cause
mortality among mixed type cancer survivors. The findings of the
current study are consistent with Currie findings and provideTable 2
Cox proportional hazards regression results for all-cause mortality a
Men
HRs (95% CIs) Metformin non-users Metformin users Non-diabetic
Model 1 1 0.775 (0.697–0.863) 0.925 (0.850–1
Model 2 1 0.741 (0.665–0.827) 1.030 (0.943–1
Model 3 1 0.762 (0.683–0.850) 1.055 (0.966–1
Model 1: Adjusted for age.
Model 2: Adjusted for body mass index, systolic blood pressure, alanine aminotransferase, total choles
Model 3: Adjusted for smoking status, drinking status, physical activity, economic status, and hyperten
5
more evidence that metformin medication after cancer diagnosis
works better to reduce overall cancer mortality than metformin
use before cancer diagnosis.
Metformin is the initial therapeutic option to manage type 2
DM with lifestyle modifications.[8] Metformin also seems to be
associated with anti-aging mechanisms. The main action
mechanisms to lower blood glucose appear to inhibit gluconeo-
genesis in liver and enhance insulin sensitivity in peripheral
tissues such as muscle.[9,18,19] However, understanding how
metformin improves survival rates among cancer survivors has
been difficult. AMPK activation and immune modulation appear
to mediate the impact of metformin on survival rate through
mammalian target of rapamycin signaling.[9,20] Inhibition of
respiratory complex protein by metformin results in reduced
adenosine triphosphate (ATP) and reactive oxygen species.[21,22]
Reduced ATP production increases the AMP:ATP ratio, which
activates AMPK that modulates energy metabolism. In addition,
metformin influences many effector proteins including mamma-
lian target of rapamycin and p53 and inhibits pro-inflammatory
processes.[23,24] These molecular and cellular mechanisms of
metformin could underlie the positive effect on improved survival
rates for cancer survivors.
In long-term cancer survivors, the fraction of primary cancer
that contributes to mortality decreases over time; however, the
incidence of death attributable to second primary cancers andccording to metformin usage and the presence of diabetes.
Women
group Metformin non-users Metformin users Non-diabetic group
.007) 1 0.868 (0.701–1.074) 0.959 (0.802–1.148)
.125) 1 0.790 (0.637–0.980) 1.058 (0.880–1.271)
.152) 1 0.805 (0.649–0.999) 1.049 (0.873–1.260)
terol, and fasting blood glucose, in addition to age in Model 1.
sion history, in addition to variables in Model 2.
Table 3
Cox proportional hazards regression results for all-cause mortality according to metformin usage and diabetes after stratification into




















Model 1 1 0.969 (0.863–1.089) 0.519 (0.443–0.607) 0.925 (0.850–1.007) 1 1.275 (1.017–1.598) 0.448 (0.330–0.607) 0.959 (0.799–1.145)
Model 2 1 0.913 (0.809–1.032) 0.522 (0.445–0.612) 1.018 (0.932–1.111) 1 1.128 (0.893–1.423) 0.434 (0.320–0.590) 1.033 (0.860–1.240)
Model 3 1 0.948 (0.839–1.071) 0.530 (0.452–0.621) 1.041 (0.953–1.137) 1 1.163 (0.921–1.469) 0.439 (0.323–0.596) 1.023 (0.852–1.228)
Model 1: adjusted for age.
Model 2: Adjusted for body mass index, systolic blood pressure, alanine aminotransferase, total cholesterol, and fasting blood glucose, in addition to age in Model 1.
Model 3: Adjusted for smoking status, drinking status, physical activity, economic status, and hypertension history in addition to variables in Model 2.
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preventing type 2 DM incidence and improving CVD-related
outcomes and their risk factors.[7,26,27] In some observational
studies, metformin was related to lower cancer incidence and
mortality.[28,29] Based on the previous indirect evidence, we
speculate that metformin reduced death from chronic diseases
such as DM and CVDs and development of second primary
cancer. These consequences may positively affect survival for
cancer survivors, especially who those took metformin after
cancer diagnosis.
This study has several advantages. First, the NHIS-HEALS
data were obtained from real-world measurements in the clinical
setting. Second, the Korean NHIS aims to maintain the
representativeness of the general Korean population. In addition,
almost the entire Korean population is engaged in obligatory
insurance and the Korean Ministry of Health and Welfare
provides free national health check-up services for adults aged 40
years or older. For these reasons, the NHIS-HEALS data are
reliable to represent the entire Korean population aged over 40
years. Third, the NHIS-HEALS data contain some laboratory
and socioeconomic information that were obtained from national
health check-up services. Laboratory findings may reflect health
status and socioeconomic status can indicate health inequity.
Both can affect medical accessibility and overall mortality.
Because these important confounding factors were available, we
could more adequately make Cox-PH regression model after
adjusting for these potential confounding factors. Fourth,
metformin users were further stratified into pre- and post-
diagnosis groups according to timing when the metformin
medication was started. Our results suggest that metformin as a
standard drug to treat diabetes might result in better mortality
outcomes than other anti-diabetic medications in diabetic
patients who are diagnosed with cancer. This is consistent with
clinical practice guidelines of diabetes from the American
Diabetes Association and European Association for the Study
of Diabetes.[8,30] Fifth, the possibility of a false-positive diagnosis
or misclassification of cancers is low. The Korean NHIS strictly
monitors malignant neoplasms because cancer patients pay less
out-of-pocket for medical costs than patients with common
diseases due to the insurance reimbursement system. Finally, the
median follow-up period is relatively longer than other studies
(4.2years). Because of the long study duration, we can assess
metformin’s long-term effect on cancer survivors.
Despite the above strengths, several limitations should be
considered when interpreting these findings. First, the level of
glycemic control was not fully controlled in individuals with
diabetes even though fasting blood glucose levels were adjusted6
for. Uncontrolled diabetes, by itself, is an important cause of
death. Thus, to improve model accuracy and reflect the effects of
diabetes severity, other markers should be adjusted. Although
fasting blood glucose level is a second option to control for the
effect of diabetes severity, glycated hemoglobin and fasting
insulin level are better indicators. If these confounders were
available in this cohort and adjusted, the Cox-PH regression
models could be more accurate in determining the association
between metformin use and overall mortality in cancer survivors
with diabetes. Second, the NHIS-HEALS data did not contain
information regarding pathologies and stages of cancers. In
addition, the NHIS does not provide all data that could be used to
identify individuals. The Korean NHIS combined sex-specific
cancers (such as prostate, breast, uterine cervix, and endometrial
cancer) and other rare cancers into 1 class, “Other,”without their
original ICD codes for de-identification. Third, detailed infor-
mation including how each cancer was treated (such as surgery,
chemotherapy, and radiotherapy), whether the primary treat-
ment was effective, and whether recurrence and relapse occurred
was not controlled.
In conclusion, metformin medication in cancer survivors with
diabetes was associated with survival benefit. In particular,
postdiagnosis metformin users were at a lower risk of all-cause
mortality, after fully adjusting for potential confounding factors.Acknowledgments
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